1) would probably lead to early embryonal or ... the potential to either inactivate the polymerase, or to form polymerase–DNA crosslinks. In the case of cancer treatment, an important strategy ...

Pharmaceuticals announced that a new patent has been granted by the Japanese Patent Office, JPO, in January 2025. This patent ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...

(NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR ... delivered earnings and revenue surprises of 3.03% and 1.63%, respectively, for the quarter ended ...

The global DNA diagnostics market is poised for remarkable expansion, with sales expected to reach USD 27,094.2 million in 2024 and a projected climb to USD 57,420.1 million by 2034. This growth ...

Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, Bldg. 1, Moscow 119991, Russia ...

Research by UMass Chan Medical School scientists Sharon Cantor, Ph.D., and Jenna M. Whalen, Ph.D., poses a new explanation ...

Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets ... the section entitled "About the Special ...

Department of Laboratory Medicine, Key Laboratory of Clinical Laboratory Technology for Precision Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350005, ...

The researchers on Viking's Octantis cruise ship are studying environmental DNA (eDNA) — bits of genetic material that float ...